Evidence map›Paper›PMID 25617631›Full record

ArticlePloS one2015

Two novel α7 nicotinic acetylcholine receptor ligands: in vitro properties and their efficacy in collagen-induced arthritis in mice.

Marjolein A van Maanen, Roger L Papke, Frieda A Koopman, Jessica Koepke, Lisette Bevaart, Roger Clark, Diana Lamppu, Daniel Elbaum, Gregory J LaRosa, Paul P Tak and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Therapeutic Targeting ofPharmacological reviews · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Neuromodulation in Inflammatory Skin Disease.Dermatology and therapy · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Marjolein A van MaanenDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Roger L PapkeDepartment of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida, United States of America.
Frieda A KoopmanDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Jessica KoepkeDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Arthrogen BV, Amsterdam, The Netherlands.
Lisette BevaartDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Arthrogen BV, Amsterdam, The Netherlands.
Roger ClarkCornerstone Therapeutics, Inc., Cary, North Carolina, United States of America.
Diana LamppuCornerstone Therapeutics, Inc., Cary, North Carolina, United States of America.
Daniel ElbaumDEC Associates, LLC, Newton, Massachusetts, United States of America.
Gregory J LaRosaCornerstone Therapeutics, Inc., Cary, North Carolina, United States of America.
Paul P TakDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Margriet J VervoordeldonkDepartment of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Arthrogen BV, Amsterdam, The Netherlands.
Academic Medical Center · NLUniversity of Amsterdam · NLFlorida College · US

Funding

Targeting of Alpha7 nAChR for therapeutic effectsR01GM057481 · NIGMS · UNIVERSITY OF FLORIDA · PI PAPKE, ROGER L · 2000 to 2023
$7.6M
NIGMS NIH HHS GM57481NIGMS NIH HHS R01 GM057481
6 · The paper itself

Abstract

introductionThe cholinergic anti-inflammatory pathway can downregulate inflammation via the release of acetylcholine (ACh) by the vagus nerve. This neurotransmitter binds to the α7 subunit of nicotinic acetylcholine receptors (α7nAChR), expressed on macrophages and other immune cells. We tested the pharmacological and functional profile of two novel compounds, PMP-311 and PMP-072 and investigated their role in modulating collagen-induced arthritis (CIA) in mice.

methodsBoth compounds were characterized with binding, electrophysiological, and pharmacokinetic studies. For in vivo efficacy studies in the CIA model the compounds were administered daily by oral gavage from day 20 till sacrifice at day 34. Disease progression was monitored by visual clinical scoring and measurement of paw swelling. Inflammation and joint destruction were examined by histology and radiology.

resultsTreatment with PMP-311 was effective in preventing disease onset, reducing clinical signs of arthritis, and reducing synovial inflammation and bone destruction. PMP-072 also showed a trend in arthritis reduction at all concentrations tested. The data showed that while both compounds bind to α7nAChR with high affinity, PMP-311 acts like a classical agonist of ion channel activity, and PMP-072 can actually act as an ion channel antagonist. Moreover, PMP-072 was clearly distinct from typical competitive antagonists, since it was able to act as a silent agonist. It synergizes with the allosteric modulator PNU-120596, and subsequently activates desensitized α7nAChR. However, PMP-072 was less efficacious than PMP-311 at both channel activation and desensitization, suggesting that both conducting and non-conducting states maybe of importance in driving an anti-inflammatory response. Finally, we found that the anti-arthritic effect can be observed despite limited penetration of the central nervous system.

conclusionsThese data provide direct evidence that the α7nAChR in immune cells does not require typical ion channel activation to exert its antiinflammatory effects.

Indexed as

Acetylcholinealpha7 Nicotinic Acetylcholine ReceptorAnilidesAnimalsArthritis, ExperimentalCell LineInflammationKnee JointLigandsMiceMice, Inbred StrainsOxazolesPC12 CellsPiperazinesPyridinesRatsAcetylcholinealpha7 Nicotinic Acetylcholine ReceptorAnilidesLigandsOxazolesPiperazinesPMP-072PMP-311Pyridines

Identifiers

PMID25617631
PMCPMC4305287
OpenAlexW2139641232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.